Accelerating early-stage asset discovery for a global pharmaceutical company

The challenge

Inpart collaborated with a global pharmaceutical company, anonymous due to competitive sensitivity, focused on developing innovative human therapeutics across multiple life science domains, including Genetic Disease and Immunometabolism.

Strengthening the R&D pipeline through external innovation and new partnerships is a core strategic priority for the company. To support this, the team sought broader access to emerging academic research and biotech assets beyond their existing networks.

However, identifying and activating a global science network across multiple therapeutic areas is complex and time-consuming. Traditional scouting approaches limited visibility into early-stage opportunities, while internal teams needed a more scalable and structured way to identify, assess, and track relevant external innovation.

The solution

To address these challenges, the company leveraged Inpart’s Connect Campaigns, a premium scouting service designed to uncover hidden, high-potential technologies, assets, and experts from Inpart’s global academic and biotech network.

Five Industry Calls for Opportunities (ICO) were deployed, each aligned with a specific R&D focus area. These campaigns enabled the company to explore multiple scientific landscapes simultaneously, while maintaining clear alignment with internal research priorities.

Understanding the need

The collaboration began with researchers at the company outlining their key scientific challenges and opportunity criteria.

Working closely with their dedicated Inpart Project and Customer Manager, the team co-developed targeted briefs for each ICO. These briefs served as strategic guides for both Inpart’s STEM experts and the wider academic and biotech community, ensuring that submissions were relevant, high quality, and aligned with the company’s objectives.

“Connect Campaigns proved extremely valuable by providing access to information on academic and biotech sectors that were not available through our existing networks, as well as insights we had not previously considered.”

Targeted outreach

Leveraging these briefs, Inpart activated its global network through a targeted outreach strategy, combining direct engagement with academic and biotech organizations and broader campaign visibility through newsletters.

This approach ensured strong reach across relevant scientific communities, while maintaining a high level of scientific relevance across all five campaigns.

The result

The campaigns generated strong engagement across academic and biotech communities. Over the six-week campaign period, a total of 227 opportunities were submitted across the five ICOs all with validated contacts, ready for partnering discussions.

All submissions were delivered through Inpart Deal, Inpart’s partnering and opportunity management platform. This provided the company with a streamlined process to review, assess, and retain a structured record of opportunities across multiple scouting initiatives.

“The process was well-organized, supported by an extremely helpful Inpart Project and Customer Manager, and delivered within an acceptable timeline.”

Targeted outreach

Ten weeks after the results were shared, the company provided feedback and, as with all Connect Campaigns, was directly introduced to the most relevant academic and biotech organizations.

To date, the campaigns have resulted in 25 introductions, initiating partnering discussions that have already delivered tangible internal impact.

Looking ahead, the company plans to leverage the insights, assets, and relationships identified through the campaigns to inform future R&D initiatives and external innovation strategies.

Inpart’s Project and Customer Manager remains closely engaged, ensuring that partnering conversations continue to progress smoothly and that the company maximizes the strategic value of the opportunities uncovered through Connect Campaigns.

“Not only did we gain access to academic and biotech organizations with whom we had no prior connection, but the campaign also led to the formation of new projects within our own company.”

Researcher

Researcher

Global Pharmaceutical Company